|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systemic treatment of oesophageal cancer显示文摘 | RICHEL D J VERVENNE W L | 2004 | Eur Gastrocnterol Hepatol2004，16，3： | 1 |
| 2 | Systemic treatment of oesophageal cancer显示文摘 | RICHEL D J VERVENNE W L | 2004 | Eur J Gastroenterol Hepatol2004，16，3： | 1 |
| 3 | Phase Ⅲ trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer显示文摘 | VAN CUTSEM E VERVENNE W L BENNOUNA J | 2009 | J Clin Oncol2009，27，13： | 1 |
| 4 | Phase III trialof bevacizumab in combination with gemcitabine and erlotinib inpatients with metastatic pancreatic cancer显示文摘 | Van Cutsem E Vervenne W L Bennouna J | 2009 | J Clin Oncol2009，27，13： | 1 |
| 5 | Malig- nant intracranial germ cell tumor treated with chemotherapy and ra- diotherapy without histopathological confirmation显示文摘 | VERVENNE W L BAKKER P J STALPERS L J | 2000 | Ned Tijdschr Geneeskd2000，144，11： | 1 |
| 6 | A randomized,double blind,placebo controlled multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlo-tinib and gemcitabine in patients with metastatic pancreatic cancer显示文摘 | Vervenne W Bennouna J Humblet Y | 2008 | J Clin Oncol2008，，： | 1 |
| 7 | A randomized, double-blind, placebo (P) controlled, muhicenter phase Ⅲ trial to evaluate the efficacy and safety ofaddingbevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer显示文摘 | Vervenne W Bennouna J Humblet Y | 2008 | J Clin Oncol2008，，： | 1 |
| 8 | Phase 1I! trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer显示文摘 | Van-Cutsem E Vervenne W L Bennouna J | 2009 | J Clin Oneol2009，27，13： | 1 |
| 9 | Systemic treatment of oesophageal cancer 显示文摘 | Richel D J Vervenne W L | 2004 | Eur Gastroenterol Hepatol2004，16，3： | 1 |
| 10 | Phase III tri- al of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer 显示文摘 | VAN C E VERVENNE W L BENNOUNA J | 2009 | J Clin Oncol2009，27，13： | 1 |
| 11 | Phase I pharmacokinetic study of the safty and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin(FOLFOX4) in patients with solid tumors 显示文摘 | Siegel-Lakhai W S Beijnen J H Vervenne W L | 2007 | Clin Cancer Res2007，13，151： | 1 |
| 12 | Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6 显示文摘 | Langermans JA Doherty TM Vervenne RA van der Laan T Lyashchenko K Greenwald R Agger EM Aagaard C Weiler H van Soolingen D Dalemans W Thomas AW Andersen P | 2005 | Vaccine2005，23，21： | 1 |
| 13 | Systemic treatment of oesophageal cancer显示文摘 | Richel D J Vervenne W L | 2004 | Eur Gastroenterol Hepatol2004，16，3： | 1 |
| 14 | A randomized, double-blind, placebo (P) controlled, muhicenter phase Ⅲ trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer显示文摘 | Vervenne W Bennonna J Humblet Y | 2008 | J Clin Oncol2008，，： | 1 |
| 15 | A randomized,double-blind,placebo(P)controlled,multicenter phase III trial to evaluatethe efficacy and safety of adding bevacizumab(B)to erlotinib(E)andgemcitabine(G)in patients(pts)with metastatic pancreatic cancer显示文摘 | Vervenne W Bennouna J Humblet Y | 2008 | J Clin Oncol2008，26，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员